Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPISTRY: Pralsetinib for RET fusion-positive solid tumors (non-NSCLC)
jRCT2031210670Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2022
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of pralsetinib in Nonhematologic neoplasms, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: IRC-assessed objective response rate (ORR) per RECIST v1.1. Started Sep 2022; status: completed.
02
Drugs
pralsetinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031210670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210670.